These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 14519651)
1. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. Wahl U; Nössner E; Kronenberger K; Gangnus R; Pohla H; Staege MS; Kolb HJ; Hallek M; Mocikat R Clin Cancer Res; 2003 Sep; 9(11):4240-6. PubMed ID: 14519651 [TBL] [Abstract][Full Text] [Related]
2. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. Mocikat R; Selmayr M; Thierfelder S; Lindhofer H Cancer Res; 1997 Jun; 57(12):2346-9. PubMed ID: 9192805 [TBL] [Abstract][Full Text] [Related]
3. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia. Kronenberger K; Nössner E; Frankenberger B; Wahl U; Dreyling M; Hallek M; Mocikat R J Immunother; 2008 Oct; 31(8):723-30. PubMed ID: 18779747 [TBL] [Abstract][Full Text] [Related]
4. Persistence of xenogenized vaccine cells in vivo. Graf N; Adam C; Mocikat R Int J Cancer; 2003 Jun; 105(2):217-20. PubMed ID: 12673682 [TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718 [TBL] [Abstract][Full Text] [Related]
6. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221 [TBL] [Abstract][Full Text] [Related]
7. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
8. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855 [TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. Allgeier T; Garhammer S; Nössner E; Wahl U; Kronenberger K; Dreyling M; Hallek M; Mocikat R Cancer Lett; 2007 Jan; 245(1-2):275-83. PubMed ID: 16516377 [TBL] [Abstract][Full Text] [Related]
10. Vaccine- and immune-based therapy in chronic lymphocytic leukemia. Le Dieu R; Gribben J Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069 [TBL] [Abstract][Full Text] [Related]
11. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802 [TBL] [Abstract][Full Text] [Related]
12. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704 [TBL] [Abstract][Full Text] [Related]
13. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation. Nelson BP; Variakojis D; Peterson LC Mod Pathol; 2002 Nov; 15(11):1111-20. PubMed ID: 12429788 [TBL] [Abstract][Full Text] [Related]
14. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera. Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243 [TBL] [Abstract][Full Text] [Related]
15. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289 [TBL] [Abstract][Full Text] [Related]
16. Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis. Nagy B; Ferrer A; Larramendy ML; Galimberti S; Aalto Y; Casas S; Vilpo J; Ruutu T; Vettenranta K; Franssila K; Knuutila S Haematologica; 2003 Jun; 88(6):654-8. PubMed ID: 12801841 [TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Os A; Bürgler S; Ribes AP; Funderud A; Wang D; Thompson KM; Tjønnfjord GE; Bogen B; Munthe LA Cell Rep; 2013 Aug; 4(3):566-77. PubMed ID: 23933259 [TBL] [Abstract][Full Text] [Related]
18. Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. Strehl J; Selmayr M; Kremer JP; Hültner L; Lindhofer H; Mocikat R Int J Cancer; 1999 Sep; 83(1):113-20. PubMed ID: 10449617 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H Leukemia; 2003 May; 17(5):894-9. PubMed ID: 12750703 [TBL] [Abstract][Full Text] [Related]
20. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]